Abstract
Background: Metastatic uveal melanoma (MUM) is associated with poor overall survival (OS) and inferior response to immune checkpoint inhibitor (ICI) therapy when compared with metastatic cutaneous melanoma. MUM-specific data to guide treatment is limited, and prognostic biomarkers are lacking.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
